More frequent liver function tests for diabetics taking Rezulin (troglitazone)

    The FDA now recommends more frequent liver function tests for diabetics taking Rezulin (troglitazone)...because of the growing concern about potential hepatotoxicity.

    There are over 150 reports of possible liver dysfunction...resulting in one liver transplant and several deaths.

    Rezulin was recently taken off the market in Great Britain. But it's staying on the market here...because the benefits seem to outweigh the risks.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote